Prevalence of HPV types in cervical specimens from an integrated healthcare delivery system: Baseline assessment to measure HPV vaccine impact

Cancer Causes and Control

Volumn 24, Issue 2, 2013, Pages 403-407

  Dunne, Eileen F ^a   Klein, Nicola P ^b   Naleway, Allison L ^c   Baxter, Roger ^b   Weinmann, Sheila ^c   Riedlinger, Karen ^c   Fetterman, Barbara ^b   Steinau, Martin ^d   Scarbrough, Mariela Z ^d   Gee, Julianne ^e   Markowitz, Lauri E ^a   Unger, Elizabeth R ^d  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b KAISER PERMANENTE   (United States)

^c CENTER FOR HEALTH RESEARCH   (United States)

^d NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

^e CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Cervical cytology; HPV; HPV vaccine; Surveillance; Vaccine impact

Indexed keywords

WART VIRUS VACCINE;

ADULT; ARTICLE; BIOASSAY; CANCER SCREENING; CHILD; CLINICAL ARTICLE; CLINICAL EVALUATION; FEMALE; GENOTYPE; HEALTH IMPACT ASSESSMENT; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; HUMAN TISSUE; INTEGRATED HEALTH CARE SYSTEM; MASS IMMUNIZATION; PAPANICOLAOU TEST; PAPILLOMAVIRUS INFECTION; PATIENT ASSESSMENT; PREVALENCE; PRIORITY JOURNAL; SCHOOL CHILD; UTERINE CERVIX CANCER; VIRUS DETECTION;

ADOLESCENT; ADULT; ALPHAPAPILLOMAVIRUS; CALIFORNIA; CHILD; DELIVERY OF HEALTH CARE, INTEGRATED; EARLY DETECTION OF CANCER; FEMALE; HUMANS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PREVALENCE; RISK FACTORS; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 84878881743     PISSN: 09575243     EISSN: 15737225     Source Type: Journal    
DOI: 10.1007/s10552-012-0085-9     Document Type: Article

References (16)

1. CDC (2010) FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP). Centers for Disease Control and Prevention (CDC). MMWR Morb Mortal Wkly Rep 59(20):626-629
2. Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER (2007) Quadrivalent human papillomavirus vaccine, recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 56(RR02):1-24
3. Dunne EF, Datta SD, Markowitz LE (2008) A review of prophylactic human papillomavirus vaccines: recommendations and monitoring in the US. Vaccine 113(10):2995-3004
4. Dunne EF, Unger ER, Sternberg M, McQuillan G, Swan DC, Patel SS, Markowitz LE (2007) Prevalence of HPV infection among females in the United States. JAMA 297:813-819
5. Hariri S, Unger ER, Sternberg M, Dunne EF, Swan D, Patel S, Markowitz LE (2011) Prevalence of genital human papillomavirus among females in the United States, the National Health and Nutrition Examination Survey, 2003-2006. J Infect Dis 204(4):566-573
6. de Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H (2004) Classification of papillomaviruses. Virology 324:17-27
7. Munoz N, Bosch FX, de Sanjose S, et al. (2003) Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348:518-527
8. Dunne EF, Sternberg M, Markowitz LE, McQuillan G, Swan D, Patel S, Unger ER (2011) Human papillomavirus (HPV) 6, 11, 16, and 18 prevalence among females in the United States-National Health and Nutrition Examination Survey, 2003-2006: opportunity to measure HPV vaccine impact? J Infect Dis 204(4):562-565
9. Manhart LE, Holmes KK, Koutsky LA, et al. (2006) Human papillomavirus infection among sexually active young women in the United States: implications for developing a vaccination strategy. Sex Transm Dis 33:502-508
10. Shikary T, Bernstein DI, Jin Y, Zimet GD, Rosenthal SL, Kahn JA (2009) Epidemiology and risk factors for human papillomavirus infection in a diverse sample of low-income young women. J Clin Virol 46:107-111
11. Gaffga NH, Flagg EW, Weinstock HS, Shlay JC, Ghanem KG, Koutsky LA, Kerndt PR, Hsu KK, Unger ER, Datta SD (2012) Monitoring HPV type-specific prevalence over time through clinic-based surveillance: a perspective on vaccine effectiveness. Vaccine 30(11):1959-1964
12. Wheeler CM, Hunt WC, Cuzick J, Langsfeld E, Pearse A, Montoya GDL, Robertson M, Shearman CA, Castle PE for The New Mexico HPV Pap Registry Steering Committee (2013) A population-based study of human papillomavirus genotype prevalence in the United States: baseline measures prior to mass human papillomavirus vaccination. Int J Cancer 132:198-207
13. Paavonen J, Naud P, Salmerón J, Wheeler CM, Chow SN, Apter D, et al., HPV PATRICIA Study Group, Greenacre M (2009) Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 374(9686):301-314
14. Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, et al. (2007) Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 356(19):1928-1943
15. The FUTURE II Study Group (2007) Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 356(19):1915-1927
16. Saslow D, et al. (2002) American cancer society guideline for the early detection of cervical neoplasia and cancer. CA Cancer J Clin 52:342-362